Earnings · US stocks

Enliven Therapeutics, Inc. (ELVN) earnings

Enliven Therapeutics, Inc. published its quarterly report on 2026-11-05. The stock moved +14.31% in the 3 trading days after the report.

Report
quarterly report
Published
2026-11-05
Result
Bad / loss
Open earnings in Wave Radar

Stock move after the report

Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.

AfterReturnvs index
1 day+10.36%—
3 days+14.31%—

Report history

Over the last 8 reports, EPS beat the consensus estimate in 4 of them. The stock rose in the 3 trading days after 4 of 8 reports (average +1.49%).

PublishedEPSEPS surprise3 days after30 days after30d vs index
2026-11-05-0.36+16.89%+14.31%——
2026-08-05-0.49-29.80%-0.47%-15.85%-14.91%
2026-05-07-0.38+7.32%+4.99%+14.07%+12.32%
2026-03-03-0.48-1.05%+2.40%+52.87%+49.99%
2025-11-12-0.32+31.18%+7.19%-19.70%-20.72%
2025-08-13-0.49-16.67%-1.18%-7.08%-9.12%
2025-05-14-0.57-13.03%-15.28%+3.97%-0.68%
2025-03-13-0.46+11.11%-0.05%-10.25%-10.11%

The last 8 reported quarters. Moves count trading days from the first tradeable session after the report; "30d vs index" is the excess return over the market index.

Stock valuations: ELVN

How to read this

Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.

Figures are generated automatically from Wave Radar's published market data and refresh after each market close.